Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib in Generalized Myasthenia Gravis
CTR20220329Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tolebrutinib in myasthenia gravis (MG), sponsored by Sanofi. Started Feb 2022; status: terminated.
02
Drugs
tolebrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20220329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220329.